Browsing Category
Pharma Industry News
4757 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Theratechnologies to unveil promising long-term efficacy for sudocetaxel zendusortide in solid tumors at ASCO 2024
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a biopharmaceutical leader focused on innovative therapy developments, has revealed Phase 1…
May 25, 2024
AbbVie completes acquisition of Landos Biopharma to strengthen immunology portfolio
AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical leader, has announced the completion of its acquisition of Landos Biopharma,…
May 25, 2024
Zentalis Pharmaceuticals reports promising results from Phase 1 trial of azenosertib, gemcitabine combo
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a trailblazer in developing small molecule therapeutics for cancer, has released the final…
May 25, 2024
Breakthrough in colorectal cancer as Regeneron Pharmaceuticals reveals promising results from immunotherapy trial
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced encouraging early outcomes from its Phase 1/2 clinical trial, which evaluates…
May 25, 2024
Zydus Lifesciences wraps up enrollment for Phase II ALS trial of Usnoflast
Zydus Lifesciences, a renowned global pharmaceutical company, has achieved a significant milestone by completing the enrollment for the…
May 24, 2024
Glenmark Pharmaceuticals reports Q4 FY2023-24 revenue of Rs 30.63bn
Glenmark Pharmaceuticals Limited, a research-led, global pharmaceutical company, today released its financial results for the fourth quarter ending…
May 24, 2024
Aptamer Group wins new contracts with global pharmaceutical leaders
Aptamer Group plc (AIM: APTA), an innovator in the life sciences sector, has announced new agreements worth up…
May 24, 2024
Avacta Group advances Phase 1 trial of oncology drug candidate AVA6000
Avacta Group plc (AIM: AVCT), a prominent life sciences company, has achieved a significant milestone in its Phase…
May 24, 2024
Eupraxia Pharmaceuticals announces promising results for EP-104GI in eosinophilic esophagitis trial
Eupraxia Pharmaceuticals Inc., listed on both TSX and NASDAQ under the ticker EPRX, has revealed encouraging results from…
May 22, 2024
Rezolute’s Phase 2 trial of RZ402 shows significant CST reduction in DME patients
Rezolute, Inc. (Nasdaq: RZLT), a leader in the development of novel therapies for serious metabolic and rare diseases,…
May 22, 2024